Min Zeng

Dr. Min Zeng

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
SCSisi Cao
Sisi Cao
ESEmily L. Shaw
Emily L. Shaw
WQWilliam R. Quarles
William R. Quarles
GSGeoffrey Y. Sasaki
Geoffrey Y. Sasaki
Priyankar DeyPriyankar Dey
Priyankar Dey
Richard BrunoRichard Bruno
Richard Bruno
Poor diet quality influences cardiometabolic risk. Although potatoes are suggested to adversely affect cardiometabolic health, controlled trials that can establish causality are limited. Consistent with potatoes being rich in micronutrients and resistant starch, we hypothesized that their inclusion in a Dietary Guidelines for Americans (DGA)-based dietary pattern would improve cardiometabolic and gut health in metabolic syndrome (MetS) persons. In a randomized cross-over trial, MetS persons (n = 27; 32.5 ± 1.3 year) consumed a DGA-based diet for 2 weeks containing potatoes (DGA + POTATO; 17.5 g/day resistant starch) or bagels (DGA + BAGEL; 0 g/day resistant starch) prior to completing oral glucose and gut permeability tests. Blood pressure, fasting glucose and insulin, and insulin resistance decreased (p < 0.05) from baseline regardless of treatment without any change in body mass. Oral glucose-induced changes in brachial artery flow-mediated dilation, nitric oxide homeostasis, and lipid peroxidation did not differ between treatment arms. Serum endotoxin AUC0–120 min and urinary lactulose/mannitol, but not urinary sucralose/erythritol, were lower in DGA + POTATO. Fecal microbiome showed limited between-treatment differences, but the proportion of acetate was higher in DGA + POTATO. Thus, short-term consumption of a DGA-based diet decreases cardiometabolic risk, and the incorporation of resistant starch-containing potatoes into a healthy diet reduces small intestinal permeability and postprandial endotoxemia.

23 July 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
APAvinash Pokala
Avinash Pokala
WQWilliam R. Quarles
William R. Quarles
JOJoana Ortega-Anaya
Joana Ortega-Anaya
RJRafael Jimenez-Flores
Rafael Jimenez-Flores
SCSisi Cao
Sisi Cao
Richard BrunoRichard Bruno
Richard Bruno
Full-fat dairy milk may protect against cardiometabolic disorders, due to the milk fat globule membrane (MFGM), through anti-inflammatory and gut-health-promoting activities. We hypothesized that a MFGM-enriched milk beverage (MEB) would alleviate metabolic endotoxemia in metabolic syndrome (MetS) persons by improving gut barrier function and glucose tolerance. In a randomized crossover trial, MetS persons consumed for two-week period a controlled diet with MEB (2.3 g/d milk phospholipids) or a comparator beverage (COMP) formulated with soy phospholipid and palm/coconut oil. They then provided fasting blood and completed a high-fat/high-carbohydrate test meal challenge for evaluating postprandial metabolism and intestinal permeability. Participants had no adverse effects and achieved high compliance, and there were no between-trial differences in dietary intakes. Compared with COMP, fasting endotoxin, glucose, incretins, and triglyceride were unaffected by MEB. The meal challenge increased postprandial endotoxin, triglyceride, and incretins, but were unaffected by MEB. Insulin sensitivity; fecal calprotectin, myeloperoxidase, and short-chain fatty acids; and small intestinal and colonic permeability were also unaffected by MEB. This short-term study demonstrates that controlled administration of MEB in MetS persons does not affect gut barrier function, glucose tolerance, and other cardiometabolic health biomarkers, which contradicts observational evidence that full-fat milk heightens cardiometabolic risk. Registered at ClinicalTrials.gov (NCT03860584).

28 August 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
SRShahabeddin Rezaei
Shahabeddin Rezaei
SCSisi Cao
Sisi Cao
MZMin Zeng
Min Zeng
MAMaria Lynn Antonius
Maria Lynn Antonius
JPJillian Pierson
Jillian Pierson
Richard BrunoRichard Bruno
Richard Bruno
Dark green leafy vegetables, such as spinach, are rich sources of α-tocopherol (α-T), a lipid-soluble antioxidant, but may contribute little to α-T status due to low intake and limited bioavailability. This study investigated whether egg co-consumption enhances α-T bioavailability from spinach and whether effects differ by egg dose, food matrix, or timing of intake. In a crossover study, healthy adults consumed deuterium-labeled (dx)-spinach (containing 5 mg dx-α-T) alone; or with 1, 2, or 3 hard-boiled eggs; 2 egg whites; or vegetable oil (9.6 g). Two exploratory trials evaluated delayed egg consumption 3 h after spinach intake. Compared with spinach alone, dx-α-T AUC0–72h (µmol/L × h) was 1.5–1.8-times higher when spinach was co-consumed with 1, 2, and 3 eggs (p ≤ 0.05), respectively, with no egg dose-dependent differences (p > 0.05). Co-ingestion of spinach with egg whites or vegetable oil increased dx-α-T AUC0–72h similar to whole eggs (p > 0.05). Delayed egg intake did not affect dx-α-T AUC0–72h relative to spinach alone (p > 0.05). Plant-derived α-T bioavailability can be improved through co-ingestion with other foods but is independent of egg dose and food matrix. Effective absorption requires concurrent intake, indicating that timing and associated digestive processes are key determinants and support food-pairing strategies to improve vitamin E bioavailability and its antioxidant contribution to plant-based diets. Registered at ClinicalTrials.gov (NCT04287816).

30 September 2025 in Journal of the American Nutrition Association
Verified
Journal Article
Open access
Sean GarveySean Garvey
Sean Garvey
TBTraci M. Blonquist
Traci M. Blonquist
LBLaura M. Brutscher
Laura M. Brutscher
DWDana M. Walsh
Dana M. Walsh
VKValerie N. Kaden
Valerie N. Kaden
JSJessica L. Spears
Jessica L. Spears
Various bacterial Bacillaceae and Bacillus strains have demonstrated health benefits, but less is known about probiotic characteristics of strains of Bacillus velezensis. In this randomized, double-blind, placebo-controlled clinical trial, we investigated the safety and efficacy of B. velezensis BV379 supplementation for 8 weeks (2 × 109 colony-forming units (CFU)/day). During the baseline and final weeks, GI symptoms were recorded daily using the 8-item Gastrointestinal Tolerance Questionnaire (GITQ). The primary outcome was the proportion of participants showing an improvement from baseline to week 8 in the 7-day, 3-item composite score for abdominal distention/bloating, burping, and gas/flatulence. Plasma chemistry, hematology, intestinal permeability, and fecal metagenomes were also investigated. Eighty participants (54% female; age: 50.3 ± 10.1 years) were randomized to BV379 (n = 39) or placebo (n = 41). At end of study, no significant difference was observed in the percentage of participants with improvement in the 3-item composite GITQ score (BV379: 36.1%; placebo: 28.2%; p = 0.46). Analysis of individual GI symptoms showed that more participants experienced improvement in abdominal distention/bloating with BV379 compared to placebo (38.9% vs 17.9%; p = 0.044). There were no clinically meaningful changes in plasma chemistry, hematology, or intestinal permeability between groups. Fecal metagenomic analyses showed no overall shifts in microbial composition between groups. In addition to B. velezensis, a few commensal species such as Lacticasei bacillus casei were significantly enriched in the BV379 group. Despite not significantly improving the composite GITQ score of distention/bloating, burping, and gas/flatulence, BV379 supplementation was a well-tolerated approach to specifically lower abdominal bloating.